Galapagos News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

26.08.24	Major Investor Says Galapagos Is 'Undervalued,' Plans To Push On Company's 'Performance' And 'Strategic Opportunities' (Benzinga)
26.08.24	Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday (Benzinga)
23.08.24	Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (GlobeNewswire)
20.08.24	Galapagos receives transparency notification from FMR LLC (GlobeNewswire)
01.08.24	Galapagos reports half-year 2024 financial results and provides second quarter business update (GlobeNewswire)
31.07.24	Ausblick: Galapagos gewährt Anlegern Blick in die Bücher (finanzen.net)
17.07.24	Erste Schätzungen: Galapagos legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net)
14.06.24	Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024 (GlobeNewswire)
30.05.24	Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future so (GlobeNewswire)
16.05.24	Galapagos creates new subscription right plans (GlobeNewswire)
15.05.24	Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S. (GlobeNewswire)
02.05.24	Galapagos reports first quarter 2024 financial results (GlobeNewswire)
01.05.24	Ausblick: Galapagos gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
30.04.24	Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024 (GlobeNewswire)
17.04.24	Erste Schätzungen: Galapagos gewährt Anlegern Blick in die Bücher (finanzen.net)
04.04.24	Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024 (GlobeNewswire)
01.04.24	Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst (Benzinga)
28.03.24	Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings (GlobeNewswire)
26.03.24	Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board (GlobeNewswire)
22.02.24	Galapagos announces full year 2023 results and outlook for 2024 (GlobeNewswire)
15.02.24	Galapagos presents at EBMT-EHA annual meeting 2024 (GlobeNewswire)
31.01.24	Galapagos completes transaction to transfer Jyseleca® business to Alfasigma (GlobeNewswire)
04.01.24	Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S. (GlobeNewswire)
03.01.24	European Drugmaker Galapagos Collaborates With Biotech BridGene Biosciences To Develop Cancer Treatments (Benzinga)
03.01.24	Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology (GlobeNewswire)
02.01.24	Galapagos signs agreement to transfer Jyseleca® business to Alfasigma (GlobeNewswire)
19.12.23	Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301 (GlobeNewswire)
09.12.23	Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101 (GlobeNewswire)
07.12.23	Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023 (GlobeNewswire)
02.11.23	Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023 (GlobeNewswire)
30.10.23	Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma (GlobeNewswire)
19.09.23	Galapagos appoints Simon Sturge to its Board of Directors (GlobeNewswire)
28.08.23	Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus (GlobeNewswire)
03.08.23	Galapagos announces first half-year 2023 financial results (GlobeNewswire)
15.06.23	Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer (GlobeNewswire)
12.06.23	Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board (GlobeNewswire)
05.06.23	Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congress (GlobeNewswire)
23.05.23	Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis (GlobeNewswire)
22.05.23	Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023 (GlobeNewswire)
05.05.23	Galapagos creates new subscription right plans (GlobeNewswire)
04.05.23	Galapagos announces first quarter 2023 financial results (GlobeNewswire)
03.05.23	Ausblick: Galapagos stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net)
02.05.23	Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer (GlobeNewswire)
26.04.23	Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Galapagos

Aktien Top/Flop

Galapagos Peer Group Nachrichten

Meistgelesene Nachrichten